Novelty exploration elicits a reversal of acute stress-induced modulation of hippocampal synaptic plasticity in the rat

J Physiol. 2006 Dec 1;577(Pt 2):601-15. doi: 10.1113/jphysiol.2006.120386. Epub 2006 Sep 28.

Abstract

Acute behavioural stress has been recognized as a strong influence on the inducibility of hippocampal long-term synaptic plasticity. We have reported previously that in adult male rats, acute behavioural stress impairs long-term potentiation (LTP) but enhances long-term depression (LTD) in the hippocampal CA1 region. In this study we report that the effects of stress on LTP and LTD were reversed when animals were introduced into a novel 'stimulus-rich' environment immediately after the stress. Novelty exploration-induced reversal of stress effects was prevented when the animals were given the NMDA receptor antagonist D-(-)-2-amino-5-phosphonopentanoic acid, the cholinergic antagonist atropine and the protein phosphatase (PP) 2B inhibitors cyclosporin A and cypermethrin, but not the alpha1-adrenergic antagonist prazosin, the beta-adrenergic antagonist propranolol or the PP1/2A inhibitor okadaic acid, respectively before being subjected to the novel environment. In addition, the ability of novelty exploration to reverse the stress effects was mimicked by a direct application of the cholinergic agonist carbachol. Exposure to the novel environment following stress was accompanied by the activation of both PP2B and striatal-enriched tyrosine phosphatase (STEP). Taken together, these findings suggest that the activation of the cholinergic system and, in turn, the triggering of an NMDA receptor-mediated activation of PP2B to increase STEP activity appear to mediate the novelty exploration-induced reversal of stress-related modulation of hippocampal long-term synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcineurin / metabolism
  • Calcineurin Inhibitors
  • Cholinergic Agonists / pharmacology
  • Cholinergic Antagonists / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Postsynaptic Potentials / drug effects
  • Exploratory Behavior*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / physiopathology*
  • Long-Term Potentiation / drug effects
  • Long-Term Synaptic Depression / drug effects
  • Male
  • Neuronal Plasticity* / drug effects
  • Patch-Clamp Techniques
  • Phosphorylation
  • Protein Tyrosine Phosphatases / metabolism
  • Protein Tyrosine Phosphatases, Non-Receptor
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cholinergic / drug effects
  • Receptors, Cholinergic / metabolism
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Stress, Psychological / metabolism
  • Stress, Psychological / physiopathology*
  • Synapses / drug effects
  • Synapses / metabolism*

Substances

  • Calcineurin Inhibitors
  • Cholinergic Agonists
  • Cholinergic Antagonists
  • Enzyme Inhibitors
  • Excitatory Amino Acid Antagonists
  • Receptors, Cholinergic
  • Receptors, N-Methyl-D-Aspartate
  • Extracellular Signal-Regulated MAP Kinases
  • Calcineurin
  • Protein Tyrosine Phosphatases
  • Protein Tyrosine Phosphatases, Non-Receptor
  • Ptpn5 protein, rat